(AOF) – Valneva today announced that the Advisory Committee on Immunization (Acip) of the United States Centers for Disease Control and Prevention (CDC) recommends the use of its single-shot chikungunya vaccine, IXCHIQ , for the prevention of disease among travelers and laboratory personnel. Acip recommends this product for people aged 18 and over traveling to a country or region with a chikungunya outbreak.
The biotech specifies that this vaccine can be considered for people traveling to a country or region without an epidemic but with evidence of transmission of the disease in the last five years, for people aged over 65 and likely to have at least moderate exposure to mosquitoes (for at least two weeks cumulatively) as well as for people traveling for a long period (six months or more, cumulatively).
Acip also recommended chikungunya vaccination for laboratory workers at risk of exposure.
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
